NCT06665594 Effect of TXA on Reducing Bruising After Filler Injection
| NCT ID | NCT06665594 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Wisconsin, Madison |
| Condition | Facial Filler Injections |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-12-05 |
| Primary Completion | 2026-11 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is: * Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection? Participants will receive the study medication along with the standard facial filler injection and complete surveys.
Eligibility Criteria
Inclusion Criteria: * Age equal to or greater than 18 but less than or equal to 89 years. * Participants interested in facial filler (HA) injection. * English speaking. Exclusion Criteria: * Minors or under the age of 18 * Participant over the age of 89 * Pregnant or breast-feeding women * Individuals unable to give consent due to another condition such as impaired decision-making capacity. * Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis * Participants undergoing unilateral facial filler (HA) injection * Participants with history of hypersensitivity to TXA or any of the other ingredients * Participants that are on current therapeutic anticoagulation therapy and aspirin use * Participants with stage 2 or greater renal failure * Participants on hemodialysis or peritoneal dialysis * History of diabetes or seizures * Current tobacco smokers * Acquired defective color vision